Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R) , used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss
In my clinical experience, the pattern is similar for both medications: Weeks 14: Nausea is most common, especially after meals
Post-surgical recovery protocols sometimes extend to twelve weeks with gradual tapering
Our team has guided hundreds of patients through GLP-1 therapy at TrimRx
The intestines naturally create GLP-1, which has a number of functions including slowing stomach emptying, promoting the production of insulin, and blocking the release of glucagon
Current clinical guidance recommends avoiding semaglutide during active lactation because animal studies show the drug passes into breast milk, and human safety data remains incomplete